Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Xiamen Amoytop Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	528.97	371.82	412.96	301.24	285.42	197.16
Trading Asset Securities	150.59	289.96	257.08	270.78	196.38	268.22
Cash & Short-Term Investments	679.56	661.79	670.04	572.02	481.8	465.38
Cash Growth	59.98%	-1.23%	17.14%	18.73%	3.53%	126.04%
Accounts Receivable	752.1	808.52	441.02	223.05	206.28	185
Other Receivables	29.79	22.34	17.87	20.17	21.67	11.99
Receivables	781.9	830.86	458.9	243.22	227.94	196.99
Inventory	321.19	263.55	187.02	129.73	116.49	99.62
Other Current Assets	87.03	70.9	24.24	10.64	8.19	10.81
Total Current Assets	1,870	1,827	1,340	955.61	834.42	772.8
Property, Plant & Equipment	786.86	686.76	490.85	389.77	192.92	126.74
Other Intangible Assets	294.39	170.85	191.54	121.69	146.91	172.28
Long-Term Deferred Tax Assets	72.21	69.09	43.66	47.18	34.96	24.97
Long-Term Deferred Charges	107.46	221.2	176.7	229.25	169.14	78.24
Other Long-Term Assets	78.6	75.35	112.98	26.05	44.99	16.24
Total Assets	3,209	3,050	2,356	1,770	1,424	1,193
Accounts Payable	85.01	57.76	39.73	50.91	8.14	7.15
Accrued Expenses	177.47	233.75	244.46	159.55	120.4	60.94
Short-Term Debt	9.9	-	-	-	10	18.92
Current Portion of Leases	5.1	5.67	4.16	4.18	5.79	-
Current Income Taxes Payable	16.12	50.27	48.95	41.97	24.42	8.73
Current Unearned Revenue	57.8	63.13	60.05	7.23	5.18	3.34
Other Current Liabilities	8.37	10.06	6.31	4.05	3.3	15.86
Total Current Liabilities	359.79	420.63	403.66	267.89	177.23	114.94
Long-Term Leases	14.14	3.27	3.76	5.56	9.37	-
Long-Term Unearned Revenue	38.89	32.96	40.62	47.68	51.25	56.84
Long-Term Deferred Tax Liabilities	0.99	0.93	0.41	15.15	5.54	3.07
Other Long-Term Liabilities	40.17	39.31	31.25	25.99	19.53	17.48
Total Liabilities	453.98	497.1	479.69	362.27	262.91	192.33
Common Stock	406.8	406.8	406.8	406.8	406.8	406.8
Additional Paid-In Capital	439.53	413.14	397.04	397.04	397.04	397.04
Retained Earnings	1,909	1,733	1,073	603.76	357.42	196.56
Shareholders' Equity	2,755	2,553	1,876	1,408	1,161	1,000
Total Liabilities & Equity	3,209	3,050	2,356	1,770	1,424	1,193
Total Debt	29.15	8.94	7.92	9.74	25.16	18.92
Net Cash (Debt)	650.41	652.85	662.11	562.28	456.63	446.46
Net Cash Growth	56.89%	-1.40%	17.76%	23.14%	2.28%	206.23%
Net Cash Per Share	1.59	1.60	1.63	1.39	1.13	1.11
Filing Date Shares Outstanding	406.8	406.8	406.8	406.8	406.8	406.8
Total Common Shares Outstanding	406.8	406.8	406.8	406.8	406.8	406.8
Working Capital	1,510	1,406	936.53	687.72	657.19	657.86
Book Value Per Share	6.77	6.28	4.61	3.46	2.85	2.46
Tangible Book Value	2,461	2,382	1,685	1,286	1,014	828.12
Tangible Book Value Per Share	6.05	5.86	4.14	3.16	2.49	2.04
Buildings	291.87	291.61	135.53	118.65	21.31	22.03
Machinery	435.97	392.63	319.97	271.83	177.83	173.49
Construction In Progress	249.97	181.56	183.72	135.81	118	68.43

Source: S&P Global Market Intelligence. Standard template. Financial Sources.